

Title: An extract of hops (*Humulus lupulus* L.) modulates gut peptide hormone secretion and reduces energy intake in healthy weight men: a randomised, cross-over clinical trial

Author Names: Edward G Walker¹, Kim R Lo¹, Malcolm C Pahl¹, Hyun Sang Shin^{3,4}, Claudia Lang¹, Mark W Wohlers¹, Sally D Poppitt³, Kevin H Sutton², John R Ingram^{1*}

Author Affiliations: ¹The New Zealand Institute for Plant and Food Research Limited, Auckland and ²Lincoln, New Zealand. ³Human Nutrition Unit; School of Biological Sciences, University of Auckland, Auckland, New Zealand. ⁴Current address: Checkmate Therapeutics Inc., Seoul, Korea.

Corresponding author: John Ingram, The New Zealand Institute for Plant and Food Research, Private Bag 92169, Auckland Mail Centre, Auckland 1142, New Zealand. Tel.: +64 9 9257119. Email: john.ingram@plantandfood.co.nz.

Sources of support: Supported by the New Zealand Ministry of Business, Innovation and Employment (MBIE) (Programme # C11X104 – Lifestyle Foods for Appetite Control)

Short running head: Hops extract reduces energy intake

Abbreviations list:

Area under the curve (AUC); bitter taste receptor (T2R); carbon dioxide (CO₂); cholecystokinin (CCK); energy intake (EI); enteroendocrine cell (EEC); gastrointestinal (GI); glucagon like peptide-1 (GLP-1); glucose-dependent insulinotropic polypeptide (GIP); glycated hemoglobin (HbA1c); human bitter taste receptor (hT2R); least significant difference (LSD); pancreatic polypeptide (PP); peptide YY (PYY); profile of mood states (POMS); visual analogue scale (VAS).

Clinical Trial Registry: ACTRN12614000434695 www.anzctr.org.au

Data described in the manuscript, code book, and analytic code will be made available upon request pending application and approval.

1 ABSTRACT

2 **Background:** Gastrointestinal enteroendocrine cells express a range of chemosensory
3 receptors involved in detecting the chemical composition of food during digestion. These
4 receptors, including bitter taste receptors (T2Rs), may play an important role in regulating gut
5 function and appetite.

6 **Objective:** To establish the ability of Amarasate[®], a bitter supercritical CO₂ extract of hops
7 (*Humulus lupulus* L.) to modify acute energy intake, appetite and hormonal responses and
8 establish a site of action.

9 **Design:** Nineteen healthy-weight (BMI = 23.5 ± 0.3 kg/m²) male volunteers completed a
10 randomised three-treatment, double blind, cross-over study with a 1 week washout between
11 treatments. Overnight-fasted participants were cannulated and provided with a standardised 2
12 MJ breakfast meal at 0900h. Treatments comprised a vehicle control (Placebo) or 500 mg of
13 hops extract administered in either delayed release capsules (Duodenal) at 1100 h or quick
14 release capsules (Gastric) at 1130 h. *Ad libitum* energy intake was recorded at an outcome
15 meal (1200 h) and afternoon snack (1400 h), with blood samples taken and subjective ratings
16 of appetite, gastrointestinal discomfort, vitality, meal palatability and mood assessed
17 throughout the day.

18 **Results:** Compared with placebo, both gastric and duodenal treatments significantly reduced
19 (p < 0.05) total *ad libitum* energy intake by 911 ± 308 kJ and 944 ± 309 kJ, respectively. Both
20 gastric and duodenal treatments significantly increased (p < 0.05) pre-meal ghrelin and post-
21 prandial CCK, GLP-1 and PYY responses while reducing postprandial insulin, GIP and PP
22 secretion with no significant impact on glycemia. In addition, gastric and duodenal
23 treatments produced small but significant (p < 0.05) changes in vitality and gastrointestinal
24 discomfort (e.g. nausea, bloating, abdominal discomfort) with mild-moderate adverse GI
25 symptoms reported in the gastric treatment only. However, no significant treatment effects
26 were observed for any subjective measures of appetite or meal palatability.

27 **Conclusion:** Both gastric and duodenal delivery of Amarasate[®] modulate the release of
28 hormones involved in appetite and glycaemic regulation, providing a potential “bitter brake”
29 on energy intake in healthy-weight men.

30

31 **Keywords:** hops, *Humulus lupulus*, appetite, satiety, homeostatic regulation, energy intake,
32 ghrelin, cholecystokinin, glucagon-like peptide-1, peptide YY, pancreatic polypeptide, blood
33 glucose, insulin, glucose-dependent insulinotropic peptide.

34 INTRODUCTION

35 Control of energy intake (EI) is central to the success of interventions designed to manage
36 body weight (1) and the consequences of obesity (2-6). The gastrointestinal (GI) tract
37 expresses an array of chemosensory receptors and transporters that provide critical inputs into
38 the acute regulation of energy intake, detecting and relaying to the brain the location,
39 chemical composition and concentration of nutritive and non-nutritive compounds in the gut
40 (7, 8). Obesity and poor weight loss outcomes are associated with impaired gut-brain axis
41 signalling (9-13) which may contribute to overeating and poor adherence to dietary restriction
42 (14-17). Approaches that restore or enhance gut-brain axis signalling may address this
43 underlying feedback dysregulation. Indeed, enhancement of gut-brain axis signalling may
44 explain many of the benefits of gastric bypass surgery (18), dietary strategies (e.g. high
45 fibre/protein) and pharmaceutical interventions (19, 20) on the control of EI. Importantly, GI
46 chemosensory mechanisms are readily accessible to dietary manipulation and represent an
47 unexploited source of weight management targets (21-23).

48 Bitter taste receptors (T2R) comprise a family of 25 G protein-coupled receptors that are
49 expressed in multiple tissues, including enteroendocrine cells (EEC) of the GI tract (24-26)
50 and are thought to have evolved a chemosensory role in the detection of potential harmful
51 substances, limiting their ingestion and absorption (27, 28). *In vitro*, T2R agonists stimulate
52 the release of peptide hormones, such as ghrelin, cholecystokinin (CCK) and glucagon-like
53 peptide-1 (GLP-1), from gut enteroendocrine cells (29-32). These gut peptide hormones play
54 a key role the homeostatic regulation of appetite, energy intake, gut function, hedonic food
55 perceptions and nutrient metabolism (33-37). A number of clinical studies using either
56 encapsulation or intragastric and intraduodenal infusion of bitter tastents have demonstrated
57 effects ranging from increased gut peptide secretion, reduced energy intake or rate of gastric
58 emptying, modifications in subjective ratings of hunger and fullness, and altered glycaemic
59 regulation (38-43), although these anorexigenic effects are inconsistent (43-46),
60 necessitating further investigation of this response.

61 Hops (*Humulus lupulus L.*) contain a range of bitter compounds including α -acids (humulone,
62 adhumulone and cohumulone) and β -acids (lupulone, adlupulone and colupulone) that are
63 known ligands for human bitter taste receptors (47). They have a long history of use as food
64 additives and bittering agents in brewing, as well as in traditional medicine [40, 41] and have
65 been shown *in vitro* to stimulate Ca^{2+} -dependent CCK release from EEC cells (32).

66 Administration of hop-derived extracts has also been shown to reduce body weight, fat mass
67 and improve glucose homeostasis in both rodent (48-55) and human studies (39, 50, 56). In
68 addition, our laboratory has demonstrated that administration of a supercritical CO₂ hop
69 extract can reduce subjective ratings of hunger during water-only fasting (57).

70 Here we investigate the efficacy and GI site of action of Amarasate[®], a bitter supercritical
71 CO₂ extract of hops, to modify acute energy intake, hormonal and glycaemic responses, and
72 subjective ratings of appetite, gastrointestinal discomfort, meal palatability and mood in
73 healthy-weight men.

74 **METHODS**

75 *Participants*

76 Healthy-weight men (18–55 years old), with a BMI between 20 and 25 kg/m² were recruited
77 by advertisement in the Auckland region, New Zealand. A telephone pre-screening interview
78 to determine eligibility of interested individuals was followed by a screening visit to verify
79 eligibility by measurement of height and weight, assessment of oral bitter taste sensitivity to
80 the hops extract, and determination of health status by self-report and blood tests (HbA1c,
81 liver function, full blood count, iron status).

82 Participants were excluded if they had a diagnosed medical condition or were on medications
83 known to affect taste, appetite-related parameters, metabolism or gastrointestinal function.

84 Exclusions also applied to participants currently on a weight-loss programme or taking
85 weight-loss medication or who had significant weight loss or gain (>5 kg) within the last six
86 months, were smokers, or had a history of alcohol or drug abuse. Participants with
87 hypersensitivities or allergies to any foods or ingredients included in the study, as well as
88 those that disliked or were unwilling to consume items listed as study foods or were
89 unwilling or unable to comply with the study protocol, or who were participating in another
90 clinical intervention trial, were also excluded.

91 All participants provided informed consent prior to clinical trial enrolment. Human ethics
92 approval was obtained from the Northern B Health and Disability Ethics committee (ref.
93 14/NTB/25) and the trial registered at the Australian and New Zealand clinical trials registry
94 (ref. ACTRN12614000434695). The study was conducted at the Consumer and Products
95 Insights facility of The New Zealand Institute for Plant and Food Research Limited
96 (Auckland, New Zealand) in March–June 2014.

97 **Study design**

98 A randomized, double-blind, placebo-controlled, 3-treatment crossover study design was
99 used to determine the efficacy and GI site of action of Amarasate[®] to modify acute energy
100 intake, appetite and postprandial hormonal responses in healthy-weight men. The three
101 treatment arms (**Supplemental Table 1**) were: Amarasate[®] (500 mg) targeted for release into
102 the stomach (gastric), Amarasate[®] (500 mg) targeted for release in the proximal small
103 intestine (duodenum), and a vehicle control (placebo). Randomisation was conducted using a
104 3x3 Latin square balanced for treatment order and carryover effects (58, 59).

105 Three one-day visits were required with a washout period of at least one week between visits.
106 The daily protocol is shown in **Figure 1**. Food intake and subjective measures of appetite,
107 gastrointestinal discomfort, vitality, meal palatability and mood were assessed during fully
108 supervised study days using standard methodology as per the recommendations of Blundell et
109 al. (60).

110 **Treatments**

111 To maintain treatment blinding, all treatments contained two sets of opaque capsules, one set
112 administered at 1100 h were delayed release capsules (DRCaps[™], size 0, Capsugel, NJ,
113 USA) designed to release their contents approximately 50–70 min after ingestion, increasing
114 the likelihood of delivery to the duodenum (61). The second set given at 1130 h were
115 standard hydroxypropyl-methylcellulose capsules (Vcaps[™], size 0, Capsugel) designed to
116 release in the stomach. The timing of capsule administration was chosen so that the treatment
117 capsules would probably have released their contents in the stomach or duodenum before the
118 *ad libitum* lunch (1200 h).


119 The three treatment groups were as follows: **Placebo** – two vehicle control delayed-release
120 capsules (1100 h) followed by two vehicle control standard-release capsules (1130 h);
121 **Gastric** – two vehicle control delayed-release capsules (1100 h) followed by two Amarasate[®]
122 standard-release capsules (1130 h); **Duodenum** – two Amarasate[®] delayed-release capsules
123 (1100 h) followed by two vehicle control standard-release capsules (1130 h).

124 Each Amarasate[®] treatment comprised two capsules, each containing 250 mg of a
125 commercially available food-safe supercritical CO₂ extract of hop cones (*Humulus lupulus* L.
126 ‘Pacific Gem’) sourced from New Zealand Hops Ltd, NZ, mixed with 125 mg of canola oil
127 as an excipient (a 2:1 hops:oil ratio). The vehicle control capsules utilised in the placebo
128 treatment and for blinding in the gastric and duodenal treatments contained 125 mg of canola

129 oil. All capsules were filled in-house using the Capsugel Profiller system (Capsugel,
130 Morristown New Jersey, USA) with a coefficient of variation of 2% for loading accuracy.
131 The α - and β -acid composition of the hop supercritical CO₂ extract comprised 51.5% total α -
132 acids (cohumulone 21.1%, humulone 22.3% and adhumulone 8.2%), and 28.3% total β -acids
133 (colupulone 19.7%, lupulone 6.0% and adlupulone 3.1%) as determined by high
134 performance liquid chromatography (HPLC) (**Supplemental Figure 1**) with reference to the
135 American Brewing Association ICE-3 standard as described in (62). The α - and β -acid
136 composition of the Amarasate[®] formulation has previously been shown to remain stable over
137 the duration of use in the current study (57).

138 *Study visits 1–3*

139 Participants arrived at the study facility by 0730 h on test days in an overnight fasted state (no
140 food or drinks apart from water since 2200 h) having abstained from excessive exercise or
141 alcohol consumption the day before. An indwelling venous cannula was inserted into a
142 forearm vein for repeated blood collection. **Figure 1** shows the study visit protocol including
143 timing of meals, treatment administration, and the collection of blood and behavioural
144 measures. During free time between the meals and questionnaires, participants remained
145 inside the facility but were free to read, watch TV or access the internet on their own devices.
146 Participants were free to leave the facility after completion of the final study questionnaire
147 and removal of the cannula at 1600 h.



149 **Figure 1.** Protocol for study visits 1–3. Participants arrived fasted (0730 h), were cannulated and provided
150 with a fixed energy (2 MJ) breakfast (0900 h) that they had to complete. Treatments along with matched
151 placebo capsules targeting the duodenum (D) or gastric (G) compartments were administered at 1100 h (T=0
152 min) and 1130 h (T= 30 min), respectively. Participants were provided with *ad libitum* lunch (1200 h) and
153 snack (1400 h) outcome meals and directed to eat until comfortably full. Blood samples (B) and VAS
154 ratings (V) of appetite, thirst, vitality and gastrointestinal discomfort related-measures were collected
155 throughout the day. Ratings of meal palatability (P) were assessed using VAS scales immediately after every
156 meal. Mood state (M) were assessed in the morning and afternoon using the Profile of Mood State
157 questionnaire. VAS, visual analogue scale; *Ad lib*, *Ad libitum*.

158 ***Fixed energy breakfast, ad libitum meals, and EI***

159 The fixed energy (2 MJ) breakfast (**Supplemental Table 2**) consisted of puffed rice cereal
160 with low fat milk and white bread with margarine and jam. Participants were instructed to
161 consume the entire breakfast within 15 min (verified by visual inspection). The outcome *ad*
162 *libitum* lunch (1200 h, T= 60 min) was a savoury buffet restricted to a beef and tomato pasta
163 sauce and boiled pasta spirals with water (250 mL). Ham sandwiches, cut into quarters with
164 the crusts removed, were provided for the outcome afternoon snack (1400 h, T= 180 min)
165 with water (250 mL). Both *ad libitum* meals were provided in excess, with participants
166 instructed that they had 30 minutes to eat until they were comfortably full. To minimise
167 distractions, all meals were provided in individual booths with participants instructed not to
168 talk, read or use mobile phones or electronic devices and to remain in the booth for the
169 designated time. Meals were weighed by two separate observers before and after
170 consumption and energy, fat, carbohydrate, and protein intake were calculated with the use of
171 the dietary software program FoodWorks (Professional Edition, version 5; Xyris Software).
172 All meals were designed to have low phytochemical content to minimise non-specific effects
173 on appetite (63).

174 ***Behavioural measures***

175 Visual analogue scales (VAS) were used to assess subjective feelings of hunger, fullness,
176 satiety, and prospective consumption following the methodology outlined in Blundell et al.
177 (60, 64). Additional VAS were used to assess thirst; measures of vitality (energy levels and
178 relaxation); GI discomfort including nausea, urge to vomit, bloating, abdominal discomfort,
179 and heartburn (adapted from (65)); and meal palatability (64) (pleasantness, visual appeal,
180 smell, taste, aftertaste and overall palatability). The VAS questions and anchor statements are
181 provided in **Supplemental Table 3**. Participants marked their responses by placing a vertical
182 line across the 100-mm scale according to subjective feelings, with responses recorded to the
183 nearest mm.

184 Changes in mood states were assessed at 1000 h (T = -60) and 1530 h (T = 270) using the
185 original version of the Profile of Mood States (POMS) questionnaire (66), a 65-item
186 inventory of six subscales: tension-anxiety, depression-dejection, anger-hostility, vigour-
187 activity, fatigue-inertia, and confusion-bewilderment. Participants rated “How are you feeling
188 right now” for each mood descriptor on a 5-point scale anchored by 1 = “not at all” and 5 =
189 “extremely”. The total mood disturbance score was computed by adding the five negative

190 subscale scores (tension, depression, anger, fatigue, confusion) and subtracting the vigour
191 score.

192 The occurrence of adverse symptoms/events were recorded for each study visit with
193 participants describing symptoms and their severity using a three-point scale of mild,
194 moderate or severe. Participants were also asked to recall any delayed symptoms/events
195 during the washout period at their next visit.

196 *Blood measurements*

197 Blood for peptide hormones analysis was collected into pre-chilled 5-mL EDTA tubes (BD
198 Vacutainer[®], USA) containing a dipeptidyl-aminopeptidase IV inhibitor (25 µL of a 2 mM
199 solution of Diprotin A, Peptides International, Osaka, Japan) and a general protease inhibitor
200 cocktail (Complete Mini EDTA-free protease inhibitor, Roche, Basel, Switzerland) (182 µL
201 of solution made up of one tablet in 2 mL of water). Blood for plasma glucose analysis was
202 collected into sodium fluoride/potassium oxalate Vacutainer[®] tubes (BD, USA). Upon
203 collection samples were immediately centrifuged (1500xg for 10 min at 4°C) and the plasma
204 snap frozen on dry ice before storage at -80°C until analysis.

205 Ghrelin (active), GLP-1 (active), PYY (total), insulin, GIP (total) and pancreatic polypeptide
206 (PP) concentrations were measured using a multiplexed magnetic bead assay (HMHMAG-
207 34K; Merck-Millipore, Massachusetts USA). Samples were assayed in duplicate and plates
208 read using a Magpix[™] system (Luminex, USA) with concentrations determined using a 5-
209 parameter curve fit in Analyst 5.1 (Miliplex, USA). Plasma CCK concentrations were
210 determined in duplicate by radioimmunoassay (EURIA-CCK, Eurodiagnostica, Sweden) as
211 per the manufacturer's instructions, with CCK standards formulated in pooled charcoal
212 stripped human plasma. Assay QC data are given in **Supplementary Table 4**. Plasma
213 glucose was analysed by Lab Services (North Shore Hospital Lab Services, Auckland) using
214 the hexokinase method on a Dimension[®] Vista 1500 (Siemens AG, Erlangen, Germany).

215 *Statistical Analysis*

216 A completers only analysis was used to address missing data. Time profile data including
217 VAS ratings and blood biomarkers were analysed with the use of a linear mixed model (SAS
218 software, PROC GLIMMIX function, version 9.4; SAS Institute Inc.) with treatment, sample
219 number, visit number and treatment order (one of six possible treatment sequences
220 allocated to each subject) and their respective interactions included as fixed effects. Fisher's
221 protected LSD was used to account for multiple testing. Where there was evidence of a main

222 treatment or treatment x time interaction ($p < 0.05$), F-tests for treatment differences at each
223 time point were conducted using the ‘slice’ command. Where these were significant ($p <$
224 0.05), Fisher’s protected LSD *post hoc* analysis was used for pairwise comparisons between
225 treatments.

226 Area under the curve (AUC) data were calculated from time 0 to 270 min for blood
227 biomarkers, and from 0 to 300 min for VAS measures, and analysed using a linear mixed
228 model (SAS 9.4) with treatment, visit number and treatment order as fixed effects..
229 Where there was evidence of a main treatment effect ($p < 0.05$), Fisher’s protected LSD was
230 used to account for multiple testing of pairwise comparisons between treatments. EI data
231 were analysed in the same way, with models fitted separately for the snack, lunch, and total
232 kJ intake measures. For meal palability measures an additional fixed factor of meal
233 (breakfast, lunch and snack) was included in the linear mixed model, while analysis of POMS
234 subscales included the fixed factor of time (pre/post). Results are presented as means \pm SEM;
235 if required, data were log transformed before analysis, with results presented as back-
236 transformed means \pm SEM. Statistical significance was assessed at $p < 0.05$.

237 **Results**

238 *Participants*

239 Of the 20 healthy-weight male participants randomly assigned into the trial, 19 completed all
240 three arms of the study, with one participant excluded for failure to comply with study
241 protocol (see CONSORT flow diagram, **Supplemental Figure 2**). Characteristics of the 19
242 participants included in the final analysis of energy intake and subjective behavioural
243 measures are shown in **Table 1**. A second participant was excluded from blood sample
244 analysis only because of repeated cannula failures and inability to obtain sufficient blood
245 volume. Hence, data on blood biomarkers is presented for 18 participants.

246

247 **Table 1.** Characteristics of the 19 male participants who completed all three treatment arms¹

	Mean ± SD	Range
Age, y	28.9 ± 10.4	18–54
Height, m	1.80 ± 0.08	1.66–1.95
Body weight, kg	76.1 ± 8.3	60.4–94.5
BMI, kg/m²	23.5 ± 1.4	20.9–25.0
Ethnicity²:		
New Zealand European	13	
Maori/Pacifica	2	
Asian	3	
Other	1	

248 ¹All measurements were recorded at the screening visit. ²Ethnicity was assessed by self-report.


249

250 ***EI at ad libitum meals***

251 The effects of treatment on EI at the outcome *ad libitum* lunch and snack meals are shown in
252 **Figure 2.** Total EI from the two outcome meals showed a highly significant effect of
253 treatment ($F_{2,34} = 6.0$, $p = 0.006$), with both the gastric (4320 ± 350 kJ, $p = 0.015$) and
254 duodenal (4287 ± 350 kJ, $p = 0.012$) treatments resulting in significant reductions compared
255 with the placebo (5231 ± 350 kJ). A significant effect of treatment ($F_{2,34} = 4.0$, $p = 0.027$) was
256 observed at the *ad libitum* snack with a reduction of EI in the duodenal treatment (1423 ± 199
257 kJ, $p = 0.044$) compared with the placebo (2018 ± 199 kJ), while the values in the gastric
258 treatment (1452 ± 199 kJ, $p = 0.056$) just failed to reach statistical significance. EI at the *ad*
259 *libitum* lunch showed no significant effect of treatment.

260

261



262

263 **Figure 2.** The effect of treatment on *ad libitum* energy intake (kJ) at the outcome lunch (1200 h),
264 snack (1400 h) and the combined intake (Total intake). Treatments comprised either a vehicle
265 control (Placebo) or a formulated hops extract (Amarasate[®]) designed to release in the stomach
266 (Gastric) or in the proximal small intestine (Duodenum). Analysis was conducted using the Mixed
267 procedure (SAS 9.4) with treatment, visit number and treatment order as factors. A significant
268 effect of treatment was observed for both the snack ($F_{2,34} = 4.0, p = 0.027$) and for total intake ($F_{2,34}$
269 $= 6.0, p = 0.006$). Fisher's LSD *post hoc* pairwise analysis demonstrated a significant ($p = 0.044$)
270 reduction in energy intake for the duodenal treatment compared with the placebo at the snack and
271 for both the gastric ($p = 0.015$) and duodenal ($p = 0.012$) treatments compared with the placebo
272 when assessed as total intake. Values are means \pm sem, ($n = 19$). * $p < 0.05$.

273 **Blood parameters**

274 **Ghrelin, CCK, GLP-1 and PYY**

275 The effects of treatment on plasma concentrations and AUC_{0-270 min} responses of the appetite
276 regulating hormones ghrelin, CCK, PYY and PP are shown in **Figure 3A–D**. All four peptide
277 hormone profiles exhibited predictable changes driven primarily by the timing of meals.

278 **Ghrelin:** Plasma concentrations of the orexigenic hormone ghrelin exhibited a significant
279 treatment x time interaction ($F_{30,440} = 1.74, p = 0.010$). Subsequent *post hoc* analysis
280 demonstrated a significant increase in ghrelin in both gastric ($p = 0.0009$) and duodenal ($p =$
281 0.004) treatments compared with the placebo, immediately prior to the *ad libitum* lunch ($T =$
282 60). No significant differences were detected between any of the treatments at any post-lunch
283 time point or for the AUC_{0-270 min} response (**Figure 3A**).

284 **CCK:** A significant main effect of treatment ($F_{2,70} = 5.8, p < 0.005$) and treatment x time
285 ($F_{30,481} = 1.9, p = 0.004$) interaction were observed for plasma concentrations of the
286 anorexigenic hormone CCK, with a similar pattern of enhanced postprandial CCK secretion
287 observed in both the gastric and duodenal treatments compared with the placebo (**Figure 3B**).

288 *Post hoc* analysis demonstrated that plasma CCK concentrations were significantly increased
289 ($p < 0.05$) in both Amarasate[®] treatments compared with the placebo at $T = 90, 150, 180,$

290 210, and 240 min. Significant increases ($p < 0.05$) were also seen at $T = 105$ and 120 min in
291 the gastric and at $T = 135$ and 270 min in the duodenal treatments compared with the
292 placebo. A significant difference between the gastric and duodenal treatments was observed
293 at the 90-min time point only ($p = 0.024$).


294 A significant effect of treatment was also seen for the CCK $AUC_{0-270 \text{ min}}$ responses ($F_{2,32} =$
295 8.66 , $p = 0.001$), with increased hormone secretion observed in both the duodenal ($p = 0.002$)
296 and gastric ($p < 0.001$) treatments compared with the placebo (**Figure 3B**). Gastric and
297 duodenal treatments did not differ significantly from each other.

298 *GLP-1*: Plasma concentrations of the insulin secretagogue and anorexigenic hormone GLP-1
299 exhibited considerable inter-individual variability (including one individual who exhibited
300 approximately forty times average baseline levels), though a significant treatment x time
301 interaction ($F_{30,422} = 1.5$, $p = 0.038$) was observed. *Post hoc* analysis demonstrated an
302 enhanced ($p < 0.05$) postprandial response to the *ad libitum* lunch in the gastric treatment at T
303 $= 90$, 105 and 150 min compared with the placebo (**Figure 3C**). The duodenal treatment
304 elicited a similarly enhanced postprandial response, with significant ($p < 0.05$) increases at T
305 $= 105$, 210 and 240 min compared with the placebo. Gastric and duodenal treatments did not
306 differ significantly from each other at any time point. No evidence for a main effect of
307 treatment was seen for GLP-1 $AUC_{0-270 \text{ min}}$ responses (**Figure 3C**).

308 *PYY*: A significant effect of treatment ($F_{2,35} = 7.6$, $p = 0.002$) and a treatment x time ($F_{30,475} =$
309 1.5 , $p = 0.042$) interaction were observed for plasma concentrations of the anorexigenic gut
310 hormone PYY (**Figure 3D**). Though considerable inter-individual variability was observed in
311 baseline concentrations (two participants were ~ 10 fold higher than average). *Post hoc*
312 analysis demonstrated that when compared with the placebo, gastric delivery of Amarasate[®]
313 produced significant increases in PYY immediately prior to the lunch ($T = 60$), with
314 differences becoming more apparent post lunch through to the end of the session ($T = 90-270$
315 min, $p < 0.05$). The PYY response to the duodenal treatment was significantly elevated
316 relative to the response in the placebo treatment only after the *ad libitum* snack at $T = 210$ and
317 240 ($p < 0.05$) minutes. A significant difference between gastric and duodenal treatments was
318 also observed at $T = -120$, 135 and 150 min ($p < 0.05$).

319 A significant effect of treatment was seen for the PYY $AUC_{0-270 \text{ min}}$ responses ($F_{2,32} = 11.14$, p
320 < 0.001), with significantly increased PYY secretion observed in the gastric compared with
321 both the duodenal ($p = 0.027$) and placebo ($p < 0.0001$) treatments. PYY release was also

322 significantly ($p = 0.023$) greater in the duodenal treatment than in the placebo (**Figure 3D**)



323

324 **Figure 3** Plasma concentrations of (A) ghrelin (active); (B) cholecystokinin (CCK); (C) glucagon like
 325 peptide-1 (active) (GLP-1) and (D) peptide YY (PYY) following administration of a control (Placebo) or
 326 Amarasate[®] targeted to either the small intestine (Duodenal) or stomach (Gastric) using delayed-release
 327 or standard capsules, respectively. Arrows indicate capsule administration; grey bars indicate the time
 328 allowed for the 2 MJ fixed energy breakfast and the *ad libitum* lunch and snack. Analysis was conducted
 329 using the mixed procedure (SAS 9.4) with treatment, time, visit number and treatment order as factors.
 330 Significant effects of treatment (B and D, $p < 0.005$) and a treatment x time interaction (A and C, $p < 0.04$)
 331 were observed. Fisher's LSD *post hoc* pairwise comparisons: gastric v placebo (* $p < 0.05$, ** $p < 0.01$, *** p
 332 < 0.001); duodenal v placebo ($\wedge p < 0.05$, $\wedge\wedge p < 0.01$, $\wedge\wedge\wedge p < 0.001$); gastric v duodenal ($\#p < 0.05$, $\#\# p <$
 333 0.01 , $\#\#\# p < 0.001$). Histograms show effect of treatment on AUC_{0-270 min} for each hormone from 0 to 270
 334 min. Analysis was conducted using the mixed procedure (SAS 9.4) with treatment, visit number and
 335 treatment order as factors. A significant effect of treatment was observed for B and D ($p = 0.001$) only,
 336 with letters denoting significantly ($p < 0.05$) different means. Values are means \pm SEM; $n = 18$. *Ad lib*, *ad*
 337 *libitum*.

338 **Glucose, Insulin, GIP and PP**

339 Effects of treatment on plasma concentrations and AUC_{0-270 min} responses of glucose, insulin,
340 GIP and PP are shown in **Figure 4A–D**.

341 *Glucose:* Changes in glucose with time (**Figure 4A**) suggest that Amarasate[®] treatment
342 modified postprandial hyperglycemia following the *ad libitum* lunch (T = 90) only. However,
343 no significant main effect of treatment or treatment x time interaction was observed for blood
344 glucose concentrations or in the glucose AUC_{0-270 min} response.

345 *Insulin:* Plasma insulin concentrations exhibited a significant effect of treatment ($F_{2,39} = 8.6$,
346 $p < 0.001$) and a treatment x time ($F_{30,332} = 1.8$, $p = 0.011$) interaction (**Figure 4B**). *Post hoc*
347 analysis demonstrated that insulin responses to the *ad libitum* lunch and snack showed a
348 significant reduction ($p < 0.05$) following the gastric and duodenal treatments at T= 90, 105,
349 120, 180 and 210 min compared with the placebo. This difference extended out to T = 240
350 min for the gastric treatment only. Insulin responses in the gastric and duodenal treatments
351 did not differ significantly from each other at any time point. A highly significant effect of
352 treatment ($F_{2,32} = 10.8$, $p = 0.0003$) was also observed in insulin AUC_{0-270 min} responses
353 (**Figure 4B**), with a reduction in postprandial insulin secretion following the gastric ($p =$
354 0.0013) and duodenal ($p = 0.0001$) treatments compared with the placebo. Insulin AUC₀₋₂₇₀
355 _{min} responses in the gastric and duodenal treatments did not differ significantly from each
356 other.


357 *GIP:* Plasma concentrations of the insulin secretagogue GIP exhibited a significant effect of
358 treatment ($F_{2,65} = 6.8$, $p < 0.002$) and a treatment x time ($F_{30,517} = 1.7$, $p = 0.010$) interaction.
359 *Post hoc* analysis demonstrated that the postprandial response to the *ad libitum* lunch and
360 snack were significantly reduced in both the gastric and duodenal treatments compared with
361 the placebo from T = 90 to 240 min ($p < 0.050$). Gastric and duodenal treatments did not
362 differ significantly from each other at any timepoint. GIP AUC_{0-270 min} responses (**Figure**
363 **4C**) exhibited a highly significant effect of treatment ($F_{2,32} = 15.5$, $p < 0.0001$), with
364 reductions in postprandial GIP secretion following the gastric ($p < 0.0001$) and duodenal (p
365 < 0.0001) treatments compared with the placebo. Gastric and duodenal treatments did not
366 differ significantly from each other.

367 *PP:* Plasma concentrations of the pancreatic hormone PP exhibited a significant effect of
368 treatment ($F_{2,69} = 8.8$, $p = 0.0004$) and a treatment x time interaction ($F_{30,491} = 1.91$, $p =$
369 0.003), increasing following meals in all treatment groups (**Figure 4D**). *Post hoc* analysis

370 demonstrated that postprandial PP responses were significantly ($p < 0.05$) reduced in both the
371 gastric ($T = 90\text{--}240$ min) and duodenal ($T = 105\text{--}210$ min) treatments compared with the
372 placebo. Duodenal and gastric treatments did not differ significantly from each other at any
373 timepoint.

374 A highly significant effect of treatment ($F_{2,32} = 11.6$, $p = 0.0002$) was seen for the PP AUC_{0-}
375 $_{270\text{ min}}$ responses, with reduced hormone secretion observed in both the duodenal ($p = 0.0096$)
376 and gastric ($p < 0.0001$) treatments compared with the placebo (**Figure 4D**). Gastric and
377 duodenal treatments did not differ significantly from each other.


378



379
 380 **Figure 4.** Plasma concentrations of (A) glucose; (B) insulin; (C) glucose-dependent insulintropic
 381 polypeptide (GIP); and (D) pancreatic polypeptide (PP) following administration of a control (Placebo)
 382 or Amarasate® targeted to either the small intestine (Duodenal) or stomach (Gastric) using delayed-
 383 release or standard capsules, respectively. Arrows indicate capsule administration; grey bars indicate
 384 the time allowed for the 2 MJ fixed energy breakfast and the *ad libitum* lunch and snack. Analysis was
 385 conducted using the mixed procedure (SAS 9.4) with treatment, time, visit number and treatment order
 386 as factors. A significant effect of treatment (B–D, $p < 0.003$) was observed. Fisher’s LSD *post hoc* pairwise
 387 comparisons: gastric v placebo (* $p < 0.05$, ** $p < 0.01$, *** $p < 0.001$); duodenal v placebo (^ $p < 0.05$, ^^ $p <$
 388 0.01 , ^^ $p < 0.001$); gastric v duodenal (# $p < 0.05$, ## $p < 0.01$, ### $p < 0.001$). Histograms show effect of
 389 treatment on AUC_{0-270 min} for each hormone from 0 to 270 min. Analysis was conducted using the mixed
 390 procedure (SAS 9.4) with treatment, visit number and treatment order as factors. A significant effect of
 391 treatment was observed for B–D ($p < 0.001$) only, with letters denoting significantly ($p < 0.05$) different
 392 means. Values are means \pm SEM; $n = 18$. *Ad lib*, *ad libitum*.

393 **VAS – appetite**

394 Effects of treatment on the subjective ratings of hunger, fullness, prospective consumption,
 395 satiety and thirst over time and as AUC_{0-300 min} are shown in **Figure 5A–E**. A predictable
 396 pattern driven by meal timing was seen in all VAS profiles. However, there was no evidence
 397 for a significant main effect of treatment or treatment x time interaction for any of the
 398 changes in VAS appetite profiles or in AUC_{0-300 min}.



400 **Figure 5** VAS ratings of (A) hunger; (B) fullness; (C) prospective consumption; (D) satiety; and (E) thirst
401 following administration of a control (Placebo) or Amarasate® targeted to either the small intestine
402 (Duodenal) or stomach (Gastric) using delayed-release or standard capsules, respectively. Arrows
403 indicate capsule administration; grey bars indicate the time allowed for the 2 MJ fixed energy breakfast
404 and the *ad libitum* lunch and snack. Analysis was conducted using the mixed procedure (SAS 9.4) with
405 treatment, time, visit number and treatment order as factors. No main effect of treatment or a treatment
406 x time interaction was observed for any measure. Histograms show mean AUC_{0-300 min} for each VAS
407 measure from 0 to 300 min. Analysis was conducted using the mixed procedure (SAS 9.4) with
408 treatment, visit number and treatment order as factors. No significant effects of treatment were seen.
409 Values are means ± SEM; n = 19. *Ad lib, ad libitum*.

410 **VAS – vitality**

411 Effects of treatment on subjective ratings of energy and relaxation are shown in

412 **Supplemental Figure 3A–B**. Ratings of energy exhibited a significant treatment effect ($F_{2,98}$
413 = 3.29, $p = 0.041$), with *post hoc* analysis demonstrating significantly ($p < 0.050$) lower
414 energy ratings in the duodenal treatment at T = 120, 135, 150 and 270 min, and in the gastric
415 treatment at T = 150 and 270 min, compared with the placebo. A significant treatment effect
416 ($F_{2,32} = 4.65$, $p = 0.017$) was also seen for AUC_{0-300 min} responses, with lower ratings for the
417 gastric ($p = 0.019$) and duodenal ($p = 0.009$) treatments compared with the placebo
418 (**Supplemental Figure 3A**). Subjective ratings of relaxation were similar throughout the day,
419 with no significant main effects of treatment or treatment x time interactions (**Supplemental**
420 **Figure 3B**).

421 **VAS – Gastrointestinal discomfort**

422 Effects of treatment on subjective ratings of nausea, urge to vomit, bloating, abdominal
423 discomfort and heartburn are shown in **Figure 6A–E**.

424 *Nausea*: Ratings of nausea (**Figure 6A**) exhibited a significant treatment effect ($F_{2,124} = 5.5$, p
425 = 0.005), with *post hoc* analysis demonstrating significantly ($p < 0.050$) higher nausea ratings
426 in the duodenal treatment at T = -30, 180, 210 and 240 min, and in the gastric treatment at T
427 = 150 and 180 min, compared with the placebo. Significant differences between the gastric
428 and duodenal treatments were seen at T = -30 and 240 min. A significant treatment effect
429 ($F_{2,32} = 10.9$, $p = 0.0002$) on AUC_{0-300 min} responses was also observed, with lower ratings in
430 the gastric ($p = 0.006$) and duodenal ($p < 0.0001$) treatments than in the placebo.

431 *Urge to vomit*: There was no evidence for a significant main effect treatment or treatment x
432 time interactions in the urge to vomit (**Figure 6B**). However, a significant treatment effect
433 ($F_{2,32} = 3.95$, $p = 0.029$) on AUC_{0-300 min} responses was seen, with a small increase in the urge
434 to vomit ($p = 0.009$) in the duodenal treatment compared with the placebo.


435 *Bloating*: A significant main effect of treatment ($F_{2,127} = 6.83$, $p = 0.002$) was seen for
436 subjective ratings of abdominal bloating (**Figure 6C**). *Post hoc* analysis demonstrated
437 significantly ($p < 0.050$) higher ratings of abdominal bloating in the duodenal treatment at T
438 = 90–150 and 240 min, and in the gastric treatment at T = 90, 135 and 150 min, than in the
439 placebo (**Figure 6C**). A significant treatment effect ($F_{2,32} = 7.8$, $p = 0.002$) was also seen on
440 $AUC_{0-300 \text{ min}}$ responses, with a small increase in bloating in the duodenal ($p = 0.001$) and
441 gastric ($p = 0.020$) treatments compared with the placebo.

442 *Abdominal discomfort*: A significant main effect of treatment ($F_{2,116} = 5.65$, $p = 0.005$) was
443 seen for ratings of abdominal discomfort (**Figure 6D**), with *post hoc* analysis demonstrating
444 significantly ($p < 0.050$) higher abdominal discomfort ratings in the duodenal treatment at T
445 = 15, 210 and 240 min, and in the gastric treatment at T = 210 min, than in the placebo.
446 Significant differences between gastric and duodenal treatments were seen at T = 15 min.
447 However, there was no evidence for a significant effect of treatment on $AUC_{0-300 \text{ min}}$.

448 *Heartburn*: No significant main effects of treatment or treatment x time interactions were
449 observed for ratings of heartburn or $AUC_{0-300 \text{ min}}$ response (**Figure 6E**).

450

451



452

453 **Figure 6** VAS ratings of (A) nausea; (B) urge to vomit; (C) bloating; (D) abdominal discomfort; and (E)
 454 heartburn following administration of a control (Placebo) or Amarasate® targeted to either the small
 455 intestine (Duodenal) or stomach (Gastric) using delayed-release or standard capsules, respectively.
 456 Arrows indicate capsule administration; grey bars indicate the time allowed for the 2 MJ fixed energy
 457 breakfast and the *ad libitum* lunch and snack. Analysis was conducted using the mixed procedure (SAS
 458 9.4) with treatment, time, visit number and treatment order as factors. A significant effect of treatment
 459 was observed for A, C and D ($p < 0.010$). Fisher's LSD *post hoc* pairwise comparisons: gastric v placebo
 460 (* $p < 0.05$, ** $p < 0.01$, *** $p < 0.001$); duodenal v placebo (^ $p < 0.05$, ^^ $p < 0.01$, ^^ $p < 0.001$); gastric v

461 duodenal (* $p < 0.05$). Histograms show effect of treatment on $AUC_{0-300 \text{ min}}$ for each VAS scale from 0 to
462 300 min. Analysis was conducted using the mixed procedure (SAS 9.4) with treatment, visit number and
463 treatment order as factors. A significant effect of treatment was observed for A–C ($p < 0.05$), with letters
464 denoting significantly ($p < 0.05$) different means. Values are means \pm SEM; $n = 19$. *Ad lib, ad libitum*.

465 ***VAS – Meal palatability***

466 There was no evidence for a main effect of treatment on VAS ratings of pleasantness, visual
467 appeal, smell, taste, aftertaste, or overall palatability for the fixed-energy breakfast or the *ad*
468 *libitum* lunch and snack outcome meals (**Supplemental Figure 4**).

469 ***Profile of mood states (POMS)***

470 The effects of treatment on the six mood subscales and total mood disturbance measured
471 prior to treatment administration (Pre) and in the POMS questionnaire are shown in
472 **Supplemental Figure 5A–G**. Only depression-dejection ($F_{2,83} = 3.4$, $p = 0.038$) and anger-
473 hostility ($F_{2,83} = 6.14$, $p = 0.003$) exhibited a significant main effect of treatment. *Post hoc*
474 analysis demonstrated a small but significant ($p = 0.011$) increase (2.3 ± 1.2) in scoring of
475 depression-dejection following the gastric treatment compared with the placebo (1.5 ± 1.2)
476 (**Supplemental Figure 5B**). Small but significant increases in ratings of anger-hostility were
477 also seen following the gastric (2.2 ± 1.2) treatment compared with the duodenal (1.5 ± 1.2 ,
478 $p = 0.016$) and placebo (1.4 ± 1.2 , $p = 0.004$) treatments (**Supplemental Figure 5C**).
479 However, these small changes in mood state may be a reflection of social and environmental
480 interactions e.g. self-entertainment activities such as watching TV, reading and socialising.

481 ***Adverse symptoms***

482 The numbers of participants reporting adverse symptoms such as loose stool/diarrhea, nausea,
483 rumbling or upset stomach, bloating and headache during the study day, and their subjective
484 ratings of severity (mild, moderate or severe) are shown in **Table 2**. The primary analysis of
485 all 19 participants revealed a total of 14 adverse symptoms, the majority of which (93%)
486 occurred while on the gastric treatment. No adverse symptoms were reported while on the
487 placebo treatment and only one individual reported a reduced frequency of defecation in the
488 week following the duodenal treatment (washout period), which may not have been
489 attributable to the treatment, given the delay. The participant excluded for failure to comply
490 with the study protocol experienced moderate-intensity loose stools and nausea in both
491 gastric and duodenal treatments and was included in a separate analysis (in brackets) of 20
492 participants for completeness.

493 **Table 2.** The effects of treatment on numbers of reported adverse symptoms and range of self-reported
494 intensities¹.

	Placebo	Gastric	Duodenal
Nausea	-	2/19 (3/20) ² mod	-(1/20) ² mod
Loose stool/diarrhea	-	6/19 (7/20) ² mild-mod	-(1/20) ² mod
Stomach rumbling	-	1/19 mild	-
Upset stomach	-	1/19 mild	-
Bloating	-	2/19 mod	-
Headache	-	1/19 mild	-
Frequency of defecation	-	-	1/19 mod ³

495 ¹ Severity of adverse events was reported using a three-point scale of mild, moderate (mod) or severe over the
496 study visit and washout period for each treatment. Treatments comprised a vehicle control (Placebo) or
497 Amarasate[®] targeted to either the small intestine (Duodenal) or stomach (Gastric) using delayed-release or
498 standard capsules, respectively. ²The participant excluded for failure to comply with the study protocol
499 experienced moderate-intensity loose stools and nausea in both gastric and duodenal treatments and was included
500 in the adverse symptom reporting as a separate analysis (in brackets) with all n=20 participants. ³One participant
501 noted a reduced frequency of defecation over the following week washout period.

502 **4. Discussion**

503 Gastrointestinal delivery of a bitter hop extract significantly decreased energy intake and
504 increased appetite-suppressing CCK, PYY and GLP-1 plasma concentrations. These changes
505 occurred without significant effects on subjective measures of appetite or the hedonic
506 properties of the test meals. However they were accompanied by small increases in
507 subjective ratings of nausea, bloating, urge to vomit and abdominal discomfort, all of which
508 are expected to decrease EI, and may be confounders. The magnitude of total EI suppression
509 (18%) is significant in the context of weight management applications (67) and compares
510 favourably with results from previous studies in humans (0–22%) that have used either
511 encapsulation, intragastric or intraduodenal delivery of a variety of bitter tastants (38, 40, 42,
512 43, 46, 68, 69).

513 The current study supports a mechanism of action involving enhanced and sustained release
514 of the anorexigenic gut hormones CCK, GLP-1 and PYY from intestinal EECs. All three gut
515 peptide hormones play a key role in the homeostatic regulation of energy intake, appetite and
516 GI function (reviewed in (70)) and have previously been shown to respond to T2R ligands
517 (29, 30, 44, 48). Maximum post-prandial increases in CCK following Amarasate[®] treatments
518 were almost 6-fold that of baseline and in the upper range reported for dietary interventions

519 (0.5–7.9 fold) (71)). Greater variability between individuals and smaller fold changes were
520 observed for GLP-1 (2.4 fold) and PYY (1.8 fold). A recent meta-analysis of CCK, GLP-1
521 and PYY infusion studies (71) that proposed that the minimum fold changes required to
522 decrease *ad libitum* energy intake were 3.6, 4.0 and 3.1-fold, respectively.

523 A significant enhancement of the orexigenic hormone ghrelin response prior to the lunch was
524 also seen for both gastric and duodenal targetting of the hop extract. This is consistent with
525 the duodenum being a source of ghrelin secretion, second only to the stomach (72, 73),
526 although pyloric reflux may also play a role (74). Gavage of T2R agonists has also been
527 shown to stimulate the secretion of ghrelin in mice, resulting in a temporary increase in food
528 intake (75). However, our results contrast with several recent reports of either unchanged or
529 suppressed ghrelin following intragastric infusion of T2R agonists (quinine, denatium
530 benzoate) in humans (41, 76), indicating potential T2R specificity in this response. The
531 mechanism(s) by which T2R agonists stimulate ghrelin secretion are poorly understood, as
532 gastric ghrelin-secreting cells are of the closed type and do not directly contact the GI lumen.

533 It is also noteworthy that there was no significant treatment-induced difference in VAS
534 measurements relating to appetite despite the significant decrease in energy intake seen with
535 both hop treatments. Although correlations between subjective assessments (e.g. hunger) and
536 behavioural effects (e.g. energy intake) are often observed, they assess fundamentally
537 different things, have been reported to show weak correlations, and do not always concur (77,
538 78). Previous studies using either gastric or duodenal delivery of T2R agonists have shown
539 effects on subjective measures of appetite in both men (79-81), and women (41, 82), although
540 many studies show no response (43-46). Interestingly, participants in the current study did
541 achieve similar feelings of fullness at the *ad libitum* test meals after consuming less food
542 when taking both hop treatments compared with the placebo. Viewed in this context,
543 Amarasate[®] treatment may modulate early satiety, which is associated with impaired gastric
544 accommodation and gastric emptying (83).

545 Glucoregulatory hormones (e.g. GLP-1, GIP, insulin) and the slowing of gastric emptying are
546 key determinants of postprandial glycemia. Bitter tastants have been shown to stimulate the
547 secretion of the incretin hormone GLP-1 from EEC cell lines (30, 48), while in mice gavage
548 of bitter gourd extract (84) or denatium benzoate (30) stimulates GLP-1 and subsequent
549 insulin secretion, leading to lowering of blood glucose. A recent study in healthy men also
550 demonstrated that intragastric and intraduodenal administration of the bitter tastant quinine
551 similarly lowered plasma glucose, increased plasma insulin and GLP-1, and slowed gastric

552 emptying (40). The current data also demonstrate an enhancement in the postprandial GLP-1
553 response following gastric and duodenal targeting of hop extract. However, this response was
554 accompanied by a substantial reduction in the postprandial insulin response, with little
555 change in plasma glucose compared with that in the placebo. Interestingly, GIP, the only gut
556 peptide hormone measured that is secreted from the enteroendocrine K-cell subtype, also
557 exhibited a substantial reduction in postprandial response following hop treatments. This is
558 contrast to the observed stimulation of CCK, GLP-1 and PYY producing EECs, suggesting
559 that K-cells lack the appropriate T2Rs.

560 GIP has been shown to be responsible for the majority of the incretin effect in healthy
561 subjects, affecting glycemic levels during the whole postprandial period (85). In contrast,
562 GLP-1 primarily affects glycaemic regulation in the early postprandial phase, delaying gastric
563 emptying and reducing plasma glucagon levels (85). GIP has also recently been demonstrated
564 as a PP secretagogue (85, 86). Hence the suppression of postprandial GIP in the hop
565 treatment groups may in part explain the suppression of insulin and PP observed.

566 GIP secretion is driven primarily by the rate of macronutrient delivery from the stomach to
567 the duodenum (i.e. rate of gastric emptying) (87). Any delay in gastric emptying in the
568 absence of a treatment induced-stimulation would potentially result in this observed decrease
569 (88-90). Although this study did not measure gastric emptying *per se*, an established action of
570 CCK, GLP-1 and PYY is to delay gastric emptying (91-93). Importantly, regulation of
571 postprandial glycemia was maintained despite reductions in GIP and insulin, indicating a
572 metabolic shift towards greater insulin sensitivity, a possible consequence of increased GLP-
573 1 secretion. Replication of these results using a fixed energy meal would be ideal, as this
574 would remove any influence from the inter-treatment differences in absolute energy intake
575 that occurred at the *ad libitum* meals.

576 Off-target effects of Amarasate[®] treatments included small (<10 mm) but significant
577 increases in subjective ratings of nausea, bloating and abdominal discomfort, which are
578 consistent with known effects of CCK, GLP-1 and PYY on upper gastrointestinal sensations
579 (94, 95). The known sedative activity of hop bitter acids may also have contributed to the
580 small decline in subjective ratings of energy following Amarasate[®] treatment (96, 97),
581 although no corresponding effect on relaxation was observed. Virtually all reported adverse
582 symptoms were associated with gastric targeting of the hops extract, with 32% of participants
583 in this treatment reporting an acute bout of mild- to moderate-intensity diarrhea. Targeting
584 delivery to the small intestine improved tolerance of the hop treatment, suggesting that gastric

585 T2Rs may play a key role in detection of ingested toxins, stimulating a host defence
586 mechanism involving net secretion of fluid and electrolytes into the intestinal lumen,
587 accelerating intestinal transit to flush harmful compounds from the GI tract in a process
588 similar to that described for T2Rs in the human and rat large intestine (98). Further
589 optimisation of the dosage of hops extract used and its timing relative to meals may also
590 contribute to a reduction in the side-effect profile.

591 The Amarasate[®] extract used in the current study is a supercritical CO₂ extract of hop
592 containing a number of hop bitter acids (e.g. cohumulone, humulone, adhumulone,
593 colupulone, lupulone and adlupulone). These α - and β -acids are potent ligands for hT2R-1,
594 14 and 40, exhibiting reported thresholds of activation as low as 3 nM (47). All three hop-
595 responsive hT2Rs have previously been identified in either the small (31) or large intestine
596 (99, 100). However, little is known regarding the profile of hT2Rs expression in specific EEC
597 cell-types. The functional data from the current study would suggest CCK, GLP-1, PYY and
598 ghrelin-producing EECs express T2R-1, 14 or 40, a T2R expression profile not shared by
599 GIP-producing EECs.

600 It is worth noting that other compounds derived from hops acids have previously been
601 examined as anti-obesity targets, and potential exists for overlapping or synergistic
602 mechanisms of action. Oxidised hop bitter acid extracts have been reported by Morimoto-
603 Kobayashi et al. to reduce fat mass in an overweight population through increased brown
604 adipose tissue thermogenesis (55, 56), with recent work in rats suggesting CCK secretion as a
605 potential mediator of this bioactivity (32). Isomerised α -acids and their derivatives have also
606 shown anti-obesogenic effects, putatively *via* metabolic regulation (39, 50), although a recent
607 report in mice highlighted a possible role for the T2Rs and anorexigenic hormones (48). Kok
608 et al. (48) showed that the synthetic substituted 1,3-cyclopentadione isomerised alpha acid
609 derivative KDT501 (KinDex Pharmaceuticals) activated T2R1 *in vitro* and when
610 administered to mice resulted in increased GLP-1, CCK and ghrelin plasma concentrations,
611 and improved glucose and insulin responses.

612 Some limitations of our study should be noted. Targeted delivery of Amarasate[®] to the
613 duodenum may not have occurred in all cases, as the press-fit delayed-release capsules used,
614 can leak (101) or disassemble (102) under gastric conditions *in vitro*. In addition, the short
615 intervals between the *ad libitum* lunch, snack and end of daily monitoring may have
616 prevented appropriate treatment differences developing in appetitive VAS measures such as
617 hunger, fullness and prospective consumption (57). The study could also have benefited from

618 the inclusion of measures of gastric emptying. However, GIP secretion is dependent upon
619 nutrient delivery to the duodenum (103) and indirectly supports delayed gastric emptying as a
620 mechanism of action. Another limitation of the study was our inclusion of only healthy-
621 weight males as participants, done to exclude the potentially confounding effects of the
622 menstrual cycle on energy intake (104) and to ensure robust appetite and glycaemic
623 regulatory mechanisms (9-13). Finally, the effect of repetitive or chronic administration of
624 hop extract on appetite regulation, including possible compensatory mechanisms and effects
625 on weight management, are unknown. Thus, further long-term studies are warranted.

626 In conclusion, both gastric and duodenal delivery of Amarasate[®], a bitter hop extract,
627 suppressed total EI and enhanced pre-meal ghrelin and postprandial CCK, GLP-1 and PYY
628 responses, providing a potential “bitter brake” on energy intake in healthy-weight males.
629 These changes occurred without significant effects on subjective measures of appetite or on
630 any measure of the hedonistic properties of the test meals though small but significant
631 increases were observed in some measures of gastrointestinal discomfort. Changes in
632 glycaemic regulation were also observed, with reductions in postprandial insulin, PP and GIP
633 responses without a significant effect on the glycaemic response to the *ad libitum* test meals.

634 These data highlight the potential of hop compounds as novel therapeutics to regulate both
635 acute energy intake and glycaemic regulation via modulation of gut peptide release and
636 delayed gastric emptying. Further studies investigating the longer-term effects of lower doses
637 of hop extract as a tool for improved weight management and glycaemic regulation should be
638 conducted, to determine potential efficacy.

639 **6. Acknowledgements**

640 The authors thank the individuals who kindly agreed to be participants in the clinical trial.
641 We would also like to thank the nurse practitioners who assisted with blood sampling during
642 the clinical trial, Dr Raina Wong for assistance with hormone analysis, Dr Ron Beatson and
643 Dave Anderson for their assistance with hops analysis and selection, and Dr Russell
644 Walmsley for providing medical oversight for this trial. We also thank Prof. Richard
645 Newcomb, Dr Roger Harker and Dr Pramod Gopal for review of the manuscript. This
646 research was funded by the New Zealand Government (NZ Ministry of Business, Innovation
647 & Employment, contract C11X1004).

648 **7. Author Contributions**

649 Contributor roles (Credit, CASRAI): conceptualization and supervision: JI; funding
650 acquisition: KS, JI; methodology: EW, JI and SP; project administration EW; investigation:
651 EW, KL, MP, HS, CL, KS and JI; data curation: JI; formal analysis MW; visualisation: EW
652 and JI ; Writing – original draft: EW, SP and JI; Writing – review & editing: All Authors.

653 **8. Conflict of Interest**

654 EW, MP, KL , CL, KS, JI are employees of The New Zealand Institute for Plant and Food
655 Research Ltd, a New Zealand Government-owned Crown Research Institute, which has a
656 royalty agreement associated with sales of the Amarasate[®] extract. The authors declare that
657 there is no individual personal financial relationship and they gain no financial incentive or
658 royalty payment outside of salaries for their employment. SDP and HS declare no conflict of
659 interest related to this product. The sponsors had no role in the design of the study, the
660 collection, analyses, or interpretation of data, in the writing of the manuscript, or in the
661 decision to publish the results.

662

663 9. References

- 664 1. Verboven K, Hansen D. Critical Reappraisal of the Role and Importance of Exercise
665 Intervention in the Treatment of Obesity in Adults. *Sports Med* 2021;51(3):379-89. doi:
666 10.1007/s40279-020-01392-8.
- 667 2. Gallagher EJ, LeRoith D. Obesity and Diabetes: The Increased Risk of Cancer and Cancer-
668 Related Mortality. *Physiol Rev* 2015;95(3):727-48. doi: 10.1152/physrev.00030.2014.
- 669 3. Lovren F, Teoh H, Verma S. Obesity and atherosclerosis: mechanistic insights. *Can J Cardiol*
670 2015;31(2):177-83. doi: 10.1016/j.cjca.2014.11.031.
- 671 4. Deng T, Lyon CJ, Bergin S, Caligiuri MA, Hsueh WA. Obesity, Inflammation, and Cancer. *Annu*
672 *Rev Pathol* 2016;11:421-49. doi: 10.1146/annurev-pathol-012615-044359.
- 673 5. Himbert C, Delphan M, Scherer D, Bowers LW, Hursting S, Ulrich CM. Signals from the
674 Adipose Microenvironment and the Obesity-Cancer Link-A Systematic Review. *Cancer Prev*
675 *Res (Phila)* 2017;10(9):494-506. doi: 10.1158/1940-6207.CAPR-16-0322.
- 676 6. Park J, Morley TS, Kim M, Clegg DJ, Scherer PE. Obesity and cancer--mechanisms underlying
677 tumour progression and recurrence. *Nat Rev Endocrinol* 2014;10(8):455-65. doi:
678 10.1038/nrendo.2014.94.
- 679 7. van der Wielen N, van Avesaat M, de Wit NJW, Vogels JTWE, Troost F, Masclee A, Koopmans
680 S-J, van der Meulen J, Boekschoten MV, Müller M, et al. Cross-Species Comparison of Genes
681 Related to Nutrient Sensing Mechanisms Expressed along the Intestine. *PloS one*
682 2014;9(9):e107531. doi: 10.1371/journal.pone.0107531.
- 683 8. Reimann F, Tolhurst G, Gribble FM. G-protein-coupled receptors in intestinal
684 chemosensation. *Cell metabolism* 2012;15(4):421-31. doi: 10.1016/j.cmet.2011.12.019.
- 685 9. Benedict C, Axelsson T, Soderberg S, Larsson A, Ingelsson E, Lind L, Schioth HB. Fat mass and
686 obesity-associated gene (FTO) is linked to higher plasma levels of the hunger hormone
687 ghrelin and lower serum levels of the satiety hormone leptin in older adults. *Diabetes*
688 2014;63(11):3955-9. doi: 10.2337/db14-0470.
- 689 10. Llewellyn CH, Trzaskowski M, van Jaarsveld CM, Plomin R, Wardle J. Satiety mechanisms in
690 genetic risk of obesity. *JAMA Pediatrics* 2014;168(4):338-44. doi:
691 10.1001/jamapediatrics.2013.4944.
- 692 11. Ranganath LR, Beety JM, Morgan LM, Wright JW, Howland R, Marks V. Attenuated GLP-1
693 secretion in obesity: cause or consequence? *Gut* 1996;38(6):916-9.
- 694 12. Batterham RL, Cohen MA, Ellis SM, Le Roux CW, Withers DJ, Frost GS, Ghatei MA, Bloom SR.
695 Inhibition of food intake in obese subjects by peptide YY3-36. *N Engl J Med*
696 2003;349(10):941-8. doi: 10.1056/NEJMoa030204.
- 697 13. Lean MEJ, Malkova D. Altered gut and adipose tissue hormones in overweight and obese
698 individuals: cause or consequence? *International journal of obesity* 2016;40(4):622-32. doi:
699 10.1038/ijo.2015.220.
- 700 14. Das SK, Gilhooly CH, Golden JK, Pittas AG, Fuss PJ, Dallal GE, McCrory MA, Saltzman E,
701 Roberts SB. Long Term Effects of Energy-Restricted Diets Differing in Glycemic Load on
702 Metabolic Adaptation and Body Composition. *Open Nutr J* 2007;85(4):1023-30.
- 703 15. Del Corral P, Chandler-Laney PC, Casazza K, Gower BA, Hunter GR. Effect of Dietary
704 Adherence with or without Exercise on Weight Loss: A Mechanistic Approach to a Global
705 Problem. *J Clin Endocrinol Metab* 2009;94(5):1602-7. doi: 10.1210/jc.2008-1057.
- 706 16. Redman LM, Heilbronn LK, Martin CK, Alfonso A, Smith SR, Ravussin E. Effect of Calorie
707 Restriction with or without Exercise on Body Composition and Fat Distribution. *The Journal*
708 *of Clinical Endocrinology & Metabolism* 2007;92(3):865-72. doi: 10.1210/jc.2006-2184.
- 709 17. Chaput JP, Doucet E, Tremblay A. Obesity: a disease or a biological adaptation? An update.
710 *Obes Rev* 2012;13(8):681-91. doi: 10.1111/j.1467-789X.2012.00992.x.
- 711 18. le Roux CW, Welbourn R, Werling M, Osborne A, Kokkinos A, Laurenus A, Lonroth H,
712 Fandriks L, Ghatei MA, Bloom SR, et al. Gut hormones as mediators of appetite and weight

- 713 loss after Roux-en-Y gastric bypass. *Ann Surg* 2007;246(5):780-5. doi:
714 10.1097/SLA.0b013e3180caa3e3.
- 715 19. Rosenstock J, Klaff LJ, Schwartz S, Northrup J, Holcombe JH, Wilhelm K, Trautmann M.
716 Effects of exenatide and lifestyle modification on body weight and glucose tolerance in
717 obese subjects with and without pre-diabetes. *Diabetes care* 2010;33(6):1173-5. doi:
718 10.2337/dc09-1203.
- 719 20. Skov AR, Toubro S, Ronn B, Holm L, Astrup A. Randomized trial on protein vs carbohydrate in
720 ad libitum fat reduced diet for the treatment of obesity. *International journal of obesity and*
721 *related metabolic disorders : journal of the International Association for the Study of Obesity*
722 1999;23(5):528-36.
- 723 21. Breen DM, Rasmussen BA, Côté CD, Jackson VM, Lam TKT. Nutrient-Sensing Mechanisms in
724 the Gut as Therapeutic Targets for Diabetes. *Diabetes* 2013;62(9):3005-13. doi:
725 10.2337/db13-0523.
- 726 22. Reimann F, Gribble FM. G protein-coupled receptors as new therapeutic targets for type 2
727 diabetes. *Diabetologia* 2016;59:229-33. doi: 10.1007/s00125-015-3825-z.
- 728 23. Janssen S, Depoortere I. Nutrient sensing in the gut: new roads to therapeutics? *Trends in*
729 *Endocrinology & Metabolism* 2013;24(2):92-100. doi:
730 <http://dx.doi.org/10.1016/j.tem.2012.11.006>.
- 731 24. Behrens M, Meyerhof W. Oral and extraoral bitter taste receptors. *Results Probl Cell Differ*
732 2010;52:87-99. doi: 10.1007/978-3-642-14426-4_8.
- 733 25. Clark AA, Liggett SB, Munger SD. Extraoral bitter taste receptors as mediators of off-target
734 drug effects. *FASEB J* 2012;26(12):4827-31. doi: 10.1096/fj.12-215087.
- 735 26. Jaggupilli A, Singh N, Upadhyaya J, Sikarwar AS, Arakawa M, Dakshinamurti S, Bhullar RP,
736 Duan K, Chelikani P. Analysis of the expression of human bitter taste receptors in extraoral
737 tissues. *Mol Cell Biochem* 2017;426(1-2):137-47. doi: 10.1007/s11010-016-2902-z.
- 738 27. Soranzo N, Bufo B, Sabeti PC, Wilson JF, Weale ME, Marguerie R, Meyerhof W, Goldstein DB.
739 Positive selection on a high-sensitivity allele of the human bitter-taste receptor TAS2R16.
740 *Curr Biol* 2005;15(14):1257-65. doi: 10.1016/j.cub.2005.06.042.
- 741 28. Sandell MA, Breslin PAS. Variability in a taste-receptor gene determines whether we taste
742 toxins in food. *Curr Biol* 2006;16(18):R792-R4. doi: DOI 10.1016/j.cub.2006.08.049.
- 743 29. Chen MC, Wu SV, Reeve JR, Jr., Rozengurt E. Bitter stimuli induce Ca²⁺ signaling and CCK
744 release in enteroendocrine STC-1 cells: role of L-type voltage-sensitive Ca²⁺ channels. *Am J*
745 *Physiol Cell Physiol* 2006;291(4):C726-39. doi: 10.1152/ajpcell.00003.2006.
- 746 30. Kim KS, Egan JM, Jang HJ. Denatonium induces secretion of glucagon-like peptide-1 through
747 activation of bitter taste receptor pathways. *Diabetologia* 2014;57(10):2117-25. doi:
748 10.1007/s00125-014-3326-5.
- 749 31. Le Neve B, Foltz M, Daniel H, Gouka R. The steroid glycoside H.g.-12 from *Hoodia gordonii*
750 activates the human bitter receptor TAS2R14 and induces CCK release from HuTu-80 cells.
751 *Am J Physiol Gastrointest Liver Physiol* 2010;299(6):G1368-75. doi:
752 10.1152/ajpgi.00135.2010.
- 753 32. Yamazaki T, Morimoto-Kobayashi Y, Koizumi K, Takahashi C, Nakajima S, Kitao S, Taniguchi Y,
754 Katayama M, Ogawa Y. Secretion of a gastrointestinal hormone, cholecystokinin, by hop-
755 derived bitter components activates sympathetic nerves in brown adipose tissue. *J Nutr*
756 *Biochem* 2018;64:80-7. doi: 10.1016/j.jnutbio.2018.10.009.
- 757 33. Gutzwiller JP, Goke B, Drewe J, Hildebrand P, Ketterer S, Handschin D, Winterhalder R,
758 Conen D, Beglinger C. Glucagon-like peptide-1: a potent regulator of food intake in humans.
759 *Gut* 1999;44(1):81-6.
- 760 34. Kissileff HR, Pi-Sunyer FX, Thornton J, Smith GP. C-terminal octapeptide of cholecystokinin
761 decreases food intake in man. *Am J Clin Nutr* 1981;34(2):154-60. doi: 10.1093/ajcn/34.2.154.

- 762 35. Goebel-Stengel M, Stengel A, Wang L, Ohning G, Tache Y, Reeve JR, Jr. CCK-8 and CCK-58
763 differ in their effects on nocturnal solid meal pattern in undisturbed rats. *Am J Physiol Regul*
764 *Integr Comp Physiol* 2012;303(8):R850-60. doi: 10.1152/ajpregu.00365.2011.
- 765 36. Schwartz GJ. The role of gastrointestinal vagal afferents in the control of food intake: current
766 prospects. *Nutrition* 2000;16(10):866-73.
- 767 37. Skibicka KP. The central GLP-1: implications for food and drug reward. *Front Neurosci*
768 2013;7:181. doi: 10.3389/fnins.2013.00181.
- 769 38. Bitarafan V, Fitzgerald PCE, Little TJ, Meyerhof W, Jones KL, Wu T, Horowitz M, Feinle-Bisset
770 C. Intra-gastric administration of the bitter tastant quinine lowers the glycemic response to a
771 nutrient drink without slowing gastric emptying in healthy men. *Am J Physiol Regul Integr*
772 *Comp Physiol* 2020;318(2):R263-R73. doi: 10.1152/ajpregu.00294.2019.
- 773 39. Obara K, Mizutani M, Hitomi Y, Yajima H, Kondo K. Isohumulones, the bitter component of
774 beer, improve hyperglycemia and decrease body fat in Japanese subjects with prediabetes.
775 *Clin Nutr* 2009;28(3):278-84. doi: 10.1016/j.clnu.2009.03.012.
- 776 40. Rose BD, Bitarafan V, Rezaie P, Fitzgerald PCE, Horowitz M, Feinle-Bisset C. Comparative
777 Effects of Intra-gastric and Intra-duodenal Administration of Quinine on the Plasma Glucose
778 Response to a Mixed-Nutrient Drink in Healthy Men: Relations with Glucoregulatory
779 Hormones and Gastric Emptying. *J Nutr* 2021. doi: 10.1093/jn/nxab020.
- 780 41. Deloof E, Janssen P, Corsetti M, Biesiekierski J, Masuy I, Rotondo A, Van Oudenhove L,
781 Depoortere I, Tack J. Intra-gastric infusion of denatonium benzoate attenuates interdigestive
782 gastric motility and hunger scores in healthy female volunteers. *Am J Clin Nutr*
783 2017;105(3):580-8. doi: 10.3945/ajcn.116.138297.
- 784 42. Iven J, Biesiekierski JR, Zhao D, Deloof E, O'Daly OG, Depoortere I, Tack J, Van Oudenhove L.
785 Intra-gastric quinine administration decreases hedonic eating in healthy women through
786 peptide-mediated gut-brain signaling mechanisms. *Nutr Neurosci* 2019;22(12):850-62. doi:
787 10.1080/1028415X.2018.1457841.
- 788 43. van Avesaat M, Troost FJ, Ripken D, Peters J, Hendriks HF, Masclee AA. Intra-duodenal
789 infusion of a combination of tastants decreases food intake in humans. *Am J Clin Nutr*
790 2015;102(4):729-35. doi: 10.3945/ajcn.115.113266.
- 791 44. Bitarafan V, Fitzgerald PCE, Little TJ, Meyerhof W, Wu T, Horowitz M, Feinle-Bisset C. Effects
792 of Intra-duodenal Infusion of the Bitter Tastant, Quinine, on Antropyloroduodenal Motility,
793 Plasma Cholecystokinin, and Energy Intake in Healthy Men. *Journal of*
794 *neurogastroenterology and motility* 2019;25(3):413-22. doi: 10.5056/jnm19036.
- 795 45. Little TJ, Gupta N, Case RM, Thompson DG, McLaughlin JT. Sweetness and bitterness taste of
796 meals per se does not mediate gastric emptying in humans. *Am J Physiol Regul Integr Comp*
797 *Physiol* 2009;297(3):R632-9. doi: 10.1152/ajpregu.00090.2009.
- 798 46. Andreozzi P, Sarnelli G, Pesce M, Zito FP, Alessandro AD, Verlezza V, Palumbo I, Turco F,
799 Esposito K, Cuomo R. The Bitter Taste Receptor Agonist Quinine Reduces Calorie Intake and
800 Increases the Postprandial Release of Cholecystokinin in Healthy Subjects. *Journal of*
801 *neurogastroenterology and motility* 2015;21(4):511-9. doi: 10.5056/jnm15028.
- 802 47. Intelmann D, Batram C, Kuhn C, Haseleu G, Meyerhof W, Hofmann T. Three TAS2R Bitter
803 Taste Receptors Mediate the Psychophysical Responses to Bitter Compounds of Hops
804 (*Humulus lupulus* L.) and Beer. *Chem Percept* 2009;2(3):118-32. doi: 10.1007/s12078-009-
805 9049-1.
- 806 48. Kok BP, Galmozzi A, Littlejohn NK, Albert V, Godio C, Kim W, Kim SM, Bland JS, Grayson N,
807 Fang M, et al. Intestinal bitter taste receptor activation alters hormone secretion and
808 imparts metabolic benefits. *Mol Metab* 2018;16:76-87. doi: 10.1016/j.molmet.2018.07.013.
- 809 49. Yajima H, Noguchi T, Ikeshima E, Shiraki M, Kanaya T, Tsuboyama-Kasaoka N, Ezaki O,
810 Oikawa S, Kondo K. Prevention of diet-induced obesity by dietary isomerized hop extract
811 containing isohumulones, in rodents. *International journal of obesity* 2005;29(8):991-7. doi:
812 10.1038/sj.ijo.0802965.

- 813 50. Yajima H, Ikeshima E, Shiraki M, Kanaya T, Fujiwara D, Odai H, Tsuboyama-Kasaoka N, Ezaki
814 O, Oikawa S, Kondo K. Isohumulones, bitter acids derived from hops, activate both
815 peroxisome proliferator-activated receptor alpha and gamma and reduce insulin resistance.
816 *J Biol Chem* 2004;279(32):33456-62. doi: 10.1074/jbc.M403456200.
- 817 51. Vroegrijk IO, van Diepen JA, van den Berg SA, Romijn JA, Havekes LM, van Dijk KW, Darland
818 G, Konda V, Tripp ML, Bland JS, et al. META060 protects against diet-induced obesity and
819 insulin resistance in a high-fat-diet fed mouse. *Nutrition* 2013;29(1):276-83. doi:
820 10.1016/j.nut.2012.05.004.
- 821 52. Tripp ML, Darland G, Konda VR, Pacioretty LM, Chang JL, Bland JS, Babish JG. Optimized
822 mixture of hops rho iso-alpha acids-rich extract and acacia proanthocyanidins-rich extract
823 reduces insulin resistance in 3T3-L1 adipocytes and improves glucose and insulin control in
824 db/db mice. *Nutr Res Pract* 2012;6(5):405-13. doi: 10.4162/nrp.2012.6.5.405.
- 825 53. Sumiyoshi M, Kimura Y. Hop (*Humulus lupulus* L.) extract inhibits obesity in mice fed a high-
826 fat diet over the long term. *Br J Nutr* 2013;109(1):162-72. doi:
827 10.1017/S000711451200061X.
- 828 54. Everard A, Geurts L, Van Roye M, Delzenne NM, Cani PD. Tetrahydro iso-alpha acids from
829 hops improve glucose homeostasis and reduce body weight gain and metabolic
830 endotoxemia in high-fat diet-fed mice. *PloS one* 2012;7(3):e33858. doi:
831 10.1371/journal.pone.0033858.
- 832 55. Morimoto-Kobayashi Y, Ohara K, Takahashi C, Kitao S, Wang G, Taniguchi Y, Katayama M,
833 Nagai K. Matured Hop Bittering Components Induce Thermogenesis in Brown Adipose Tissue
834 via Sympathetic Nerve Activity. *PloS one* 2015;10(6):e0131042. doi:
835 10.1371/journal.pone.0131042.
- 836 56. Morimoto-Kobayashi Y, Ohara K, Ashigai H, Kanaya T, Koizumi K, Manabe F, Kaneko Y,
837 Taniguchi Y, Katayama M, Kowatari Y, et al. Matured hop extract reduces body fat in healthy
838 overweight humans: a randomized, double-blind, placebo-controlled parallel group study.
839 *Nutr J* 2016;15:25. doi: 10.1186/s12937-016-0144-2.
- 840 57. Walker E, Lo K, Tham S, Pahl M, Lomiwes D, Cooney J, Wohlers M, Gopal P. New Zealand
841 Bitter Hops Extract Reduces Hunger During a 24 h Water Only Fast. *Nutrients* 2019;11(11).
842 doi: 10.3390/nu11112754.
- 843 58. Williams EJ. Experimental Designs Balanced for the Estimation of Residual Effects of
844 Treatments. *Australian Journal of Chemistry* 1949;2(2):149-68. doi: 10.1071/ch9490149.
- 845 59. John PWM. Statistical Design and Analysis of Experiments. New York: Macmillan, 1971.
- 846 60. Blundell J, de Graaf C, Hulshof T, Jebb S, Livingstone B, Lluch A, Mela D, Salah S, Schuring E,
847 van der Knaap H, et al. Appetite control: methodological aspects of the evaluation of foods.
848 *Obes Rev* 2010;11(3):251-70. doi: 10.1111/j.1467-789X.2010.00714.x.
- 849 61. Amo R. DRcaps® Capsules Achieve Delayed Release Properties for Nutritional Ingredients in
850 Human Clinical Study. Capsugel, 2014. no. BAS 420.]
- 851 62. Committee EBCA. Analytica EBC, European Brewery Convention, Method 7.8. 5th ed.
852 Nürnberg: Verlag Hans Carl Getränke-Fachverlag, 1998.
- 853 63. Tucci SA. Phytochemicals in the Control of Human Appetite and Body Weight.
854 *Pharmaceuticals (Basel)* 2010;3(3):748-63. doi: 10.3390/ph3030748.
- 855 64. Flint A, Raben A, Blundell JE, Astrup A. Reproducibility, power and validity of visual analogue
856 scales in assessment of appetite sensations in single test meal studies. *International journal*
857 *of obesity* 2000;24(1):38-48.
- 858 65. Bovenschen HJ, Janssen MJR, van Oijen MGH, Laheij RJF, van Rossum LGM, Jansen JBMJ.
859 Evaluation of a gastrointestinal symptoms questionnaire. *Digest Dis Sci* 2006;51(9):1509-15.
860 doi: 10.1007/s10620-006-9120-6.
- 861 66. McNair DM, Lorr M, Droppelman LF. Manual for the profile of mood states. San Diego, CA.:
862 Educational and Industrial Testing Service, 1971.

- 863 67. Mozaffarian D, Hao T, Rimm EB, Willett WC, Hu FB. Changes in diet and lifestyle and long-
864 term weight gain in women and men. *N Engl J Med* 2011;364(25):2392-404. doi:
865 10.1056/NEJMoa1014296.
- 866 68. Mennella I, Fogliano V, Ferracane R, Arlorio M, Pattarino F, Vitaglione P. Microencapsulated
867 bitter compounds (from *Gentiana lutea*) reduce daily energy intakes in humans. *Br J Nutr*
868 2016;116:1841-50. doi: 10.1017/s0007114516003858.
- 869 69. Bitarafan V, Fitzgerald PCE, Little TJ, Meyerhof W, Wu T, Horowitz M, Feinle-Bisset C. Effects
870 of Intraduodenal Infusion of the Bitter Tastant, Quinine, on Antropyloroduodenal Motility,
871 Plasma Cholecystokinin, and Energy Intake in Healthy Men. *Journal of*
872 *neurogastroenterology and motility* 2019. doi: 10.5056/jnm19036.
- 873 70. Steinert RE, Feinle-Bisset C, Asarian L, Horowitz M, Beglinger C, Geary N. Ghrelin, CCK, GLP-1,
874 and PYY(3-36): Secretory Controls and Physiological Roles in Eating and Glycemia in Health,
875 Obesity, and After RYGB. *Physiol Rev* 2017;97(1):411-63. doi: 10.1152/physrev.00031.2014.
- 876 71. Lim JJ, Poppitt SD. How Satiating Are the 'Satiety' Peptides: A Problem of Pharmacology
877 versus Physiology in the Development of Novel Foods for Regulation of Food Intake.
878 *Nutrients* 2019;11(7). doi: 10.3390/nu11071517.
- 879 72. Date Y, Kojima M, Hosoda H, Sawaguchi A, Mondal MS, Suganuma T, Matsukura S, Kangawa
880 K, Nakazato M. Ghrelin, a novel growth hormone-releasing acylated peptide, is synthesized
881 in a distinct endocrine cell type in the gastrointestinal tracts of rats and humans.
882 *Endocrinology* 2000;141(11):4255-61. doi: 10.1210/endo.141.11.7757.
- 883 73. Wang HT, Lu QC, Wang Q, Wang RC, Zhang Y, Chen HL, Zhao H, Qian HX. Role of the
884 duodenum in regulation of plasma ghrelin levels and body mass index after subtotal
885 gastrectomy. *World J Gastroenterol* 2008;14(15):2425-9. doi: 10.3748/wjg.14.2425.
- 886 74. Muller-Lissner SA, Fimmel CJ, Sonnenberg A, Will N, Muller-Duysing W, Heinzl F, Muller R,
887 Blum AL. Novel approach to quantify duodenogastric reflux in healthy volunteers and in
888 patients with type I gastric ulcer. *Gut* 1983;24(6):510-8.
- 889 75. Janssen S, Laermans J, Verhulst PJ, Thijs T, Tack J, Depoortere I. Bitter taste receptors and
890 alpha-gustducin regulate the secretion of ghrelin with functional effects on food intake and
891 gastric emptying. *Proc Natl Acad Sci U S A* 2011;108(5):2094-9. doi:
892 10.1073/pnas.1011508108.
- 893 76. Deloose E, Corsetti M, Van Oudenhove L, Depoortere I, Tack J. Intragastric infusion of the
894 bitter tastant quinine suppresses hormone release and antral motility during the fasting
895 state in healthy female volunteers. *Neurogastroenterol Motil* 2018;30(1). doi:
896 10.1111/nmo.13171.
- 897 77. Sadoul BC, Schuring EA, Mela DJ, Peters HP. The relationship between appetite scores and
898 subsequent energy intake: an analysis based on 23 randomized controlled studies. *Appetite*
899 2014;83:153-9. doi: 10.1016/j.appet.2014.08.016.
- 900 78. Poppitt SD, Han S, Strik CM, Kindleysides S, Chan YK. Investigating acute satiation and meal
901 termination effects of a commercial lipid emulsion: A breakfast meal study. *Physiology &*
902 *behavior* 2015;152(Pt A):20-5. doi: 10.1016/j.physbeh.2015.09.008.
- 903 79. Deloose E, Corsetti M, Van Oudenhove L, Depoortere I, Tack JF. In man intragastric
904 administration of the bitter compound denatonium benzoate decreases hunger and the
905 occurrence of gastric phase III in the fasting state. *Gastroenterology* 2013;144(5):S548-S. doi:
906 10.1016/S0016-5085(13)62032-6.
- 907 80. Verschueren S, Janssen P, Andrews CN, Verbeke K, Depoortere I, Tack JF. The Effect of the
908 Bitter Taste Receptor Agonist Denatonium Benzoate on Gastric Emptying, Satiety and Return
909 of Hunger After a Meal in Healthy Volunteers. *Gastroenterology* 2013;144(5):S548.
- 910 81. Avau B, Rotondo A, Thijs T, Andrews CN, Janssen P, Tack J, Depoortere I. Targeting extra-oral
911 bitter taste receptors modulates gastrointestinal motility with effects on satiation. *Sci Rep*
912 2015;5:15985. doi: 10.1038/srep15985.

- 913 82. Iven J, Biesiekierski JR, Zhao D, Deloouse E, O'Daly OG, Depoortere I, Tack J, Van Oudenhove L.
914 Intra-gastric quinine administration decreases hedonic eating in healthy women through
915 peptide-mediated gut-brain signaling mechanisms. *Nutr Neurosci* 2018;1-13. doi:
916 10.1080/1028415x.2018.1457841.
- 917 83. Piessevaux H, Tack J, Walrand S, Pauwels S, Geubel A. Intra-gastric distribution of a
918 standardized meal in health and functional dyspepsia: correlation with specific symptoms.
919 *Neurogastroenterol Motil* 2003;15(5):447-55. doi: 10.1046/j.1365-2982.2003.00431.x.
- 920 84. Huang TN, Lu KN, Pai YP, Chin H, Huang CJ. Role of GLP-1 in the Hypoglycemic Effects of Wild
921 Bitter Gourd. *Evid Based Complement Alternat Med* 2013;2013:625892. doi:
922 10.1155/2013/625892.
- 923 85. Gasbjerg LS, Helsted MM, Hartmann B, Jensen MH, Gabe MBN, Sparre-Ulrich AH, Veedfald S,
924 Stensen S, Lanng AR, Bergmann NC, et al. Separate and Combined Glucometabolic Effects of
925 Endogenous Glucose-Dependent Insulinotropic Polypeptide and Glucagon-like Peptide 1 in
926 Healthy Individuals. *Diabetes* 2019;68(5):906-17. doi: 10.2337/db18-1123.
- 927 86. Veedfald S, Vedtofte L, Skov-Jepesen K, Deacon CF, Hartmann B, Vilsboll T, Knop FK,
928 Christensen MB, Holst JJ. Glucose-Dependent Insulinotropic Polypeptide Is a Pancreatic
929 Polypeptide Secretagogue in Humans. *J Clin Endocrinol Metab* 2020;105(3):e502-e10. doi:
930 10.1210/clinem/dgz097.
- 931 87. Pilichiewicz AN, Chaikomin R, Brennan IM, Wishart JM, Rayner CK, Jones KL, Smout AJ,
932 Horowitz M, Feinle-Bisset C. Load-dependent effects of duodenal glucose on glycemia,
933 gastrointestinal hormones, antropyloroduodenal motility, and energy intake in healthy men.
934 *Am J Physiol Endocrinol Metab* 2007;293(3):E743-53. doi: 10.1152/ajpendo.00159.2007.
- 935 88. Wilson RM, Boden G, Owen OE. Pancreatic polypeptide responses to a meal and to
936 intraduodenal amino acids and sodium oleate. *Endocrinology* 1978;102(3):859-63. doi:
937 10.1210/endo-102-3-859.
- 938 89. Batterham RL, Le Roux CW, Cohen MA, Park AJ, Ellis SM, Patterson M, Frost GS, Ghatei MA,
939 Bloom SR. Pancreatic polypeptide reduces appetite and food intake in humans. *J Clin*
940 *Endocrinol Metab* 2003;88(8):3989-92. doi: 10.1210/jc.2003-030630.
- 941 90. Krarup T, Holst JJ, Larsen KL. Responses and molecular heterogeneity of IR-GIP after
942 intraduodenal glucose and fat. *Am J Physiol* 1985;249(2 Pt 1):E195-200. doi:
943 10.1152/ajpendo.1985.249.2.E195.
- 944 91. Yamagishi T, Debas HT. Cholecystokinin inhibits gastric emptying by acting on both proximal
945 stomach and pylorus. *Am J Physiol* 1978;234(4):E375-8. doi:
946 10.1152/ajpendo.1978.234.4.E375.
- 947 92. Naslund E, Bogefors J, Gryback P, Bjellerup P, Jacobsson H, Holst JJ, Hellstrom PM. GLP-1
948 inhibits gastric emptying of water but does not influence plasma. *Scand J Gastroenterol*
949 2001;36(2):156-62.
- 950 93. Naslund E, Bogefors J, Skogar S, Gryback P, Jacobsson H, Holst JJ, Hellstrom PM. GLP-1 slows
951 solid gastric emptying and inhibits insulin, glucagon, and PYY release in humans. *Am J Physiol*
952 1999;277(3):R910-6. doi: 10.1152/ajpregu.1999.277.3.R910.
- 953 94. Fried M, Feinle C. The role of fat and cholecystokinin in functional dyspepsia. *Gut* 2002;51
954 *Suppl 1*:i54-7. doi: 10.1136/gut.51.suppl_1.i54.
- 955 95. Bettge K, Kahle M, Abd El Aziz MS, Meier JJ, Nauck MA. Occurrence of nausea, vomiting and
956 diarrhoea reported as adverse events in clinical trials studying glucagon-like peptide-1
957 receptor agonists: A systematic analysis of published clinical trials. *Diabetes Obes Metab*
958 2017;19(3):336-47. doi: 10.1111/dom.12824.
- 959 96. Franco L, Sanchez C, Bravo R, Rodriguez AB, Barriga C, Romero E, Cubero J. The sedative
960 effect of non-alcoholic beer in healthy female nurses. *PloS one* 2012;7(7):e37290. doi:
961 10.1371/journal.pone.0037290.
- 962 97. Zanolli P, Zavatti M. Pharmacognostic and pharmacological profile of *Humulus lupulus* L.
963 *Journal of ethnopharmacology* 2008;116(3):383-96. doi: 10.1016/j.jep.2008.01.011.

- 964 98. Kaji I, Karaki S, Fukami Y, Terasaki M, Kuwahara A. Secretory effects of a luminal bitter
965 tastant and expressions of bitter taste receptors, T2Rs, in the human and rat large intestine.
966 *Am J Physiol Gastrointest Liver Physiol* 2009;296(5):G971-81. doi: 10.1152/ajpgi.90514.2008.
- 967 99. Rozengurt N, Wu SV, Chen MC, Huang C, Sternini C, Rozengurt E. Colocalization of the alpha-
968 subunit of gustducin with PYY and GLP-1 in L cells of human colon. *Am J Physiol Gastrointest*
969 *Liver Physiol* 2006;291(5):G792-802. doi: 10.1152/ajpgi.00074.2006.
- 970 100. Kaji I, Karaki S-i, Fukami Y, Terasaki M, Kuwahara A. Secretory effects of a luminal bitter
971 tastant and expressions of bitter taste receptors, T2Rs, in the human and rat large intestine.
972 *Am J Physiol Gastrointest Liver Physiol* 2009;296(5):G971-81. doi: 10.1152/ajpgi.90514.2008.
- 973 101. Al-Tabakha MM, Arida AI, Fehelbom KMS, Sadek B, Abu Jarad RA. Performances of New
974 Generation of Delayed Release Capsules. *J Young Pharm* 2015;7(1):36-44. doi:
975 10.5530/jyp.2015.1.7.
- 976 102. Miller DS, Parsons AM, Bresland J, Herde P, Pham DM, Tan A, Hsu HY, Prestidge CA, Kuchel T,
977 Begg R, et al. A simple and inexpensive enteric-coated capsule for delivery of acid-labile
978 macromolecules to the small intestine. *J Zhejiang Univ Sci B* 2015;16(7):586-92. doi:
979 10.1631/jzus.B1400290.
- 980 103. Reimann F, Diakogiannaki E, Moss CE, Gribble FM. Cellular mechanisms governing glucose-
981 dependent insulinotropic polypeptide secretion. *Peptides* 2020;125:170206. doi:
982 10.1016/j.peptides.2019.170206.
- 983 104. Brennan IM, Feltrin KL, Nair NS, Hausken T, Little TJ, Gentilcore D, Wishart JM, Jones KL,
984 Horowitz M, Feinle-Bisset C. Effects of the phases of the menstrual cycle on gastric
985 emptying, glycemia, plasma GLP-1 and insulin, and energy intake in healthy lean women. *Am*
986 *J Physiol Gastrointest Liver Physiol* 2009;297(3):G602-10. doi: 10.1152/ajpgi.00051.2009.
- 987